// App-Quantinova.ai

5022.0 : Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Researchers

Presenter

  • Peter C. Black

Principal Investigators

  • Catherine Tangen

  • Parminder Singh

  • David James McConkey

  • Scott Lucia

  • William Thomas Lowrance

  • Vadim S Koshkin

  • Kelly Lynn Stratton

  • Trinity Bivalacqua

  • Elad Sharon

  • Wassim Kassouf

  • Sima P. Porten

  • Richard Carlton Bangs

  • Melissa Plets

  • Seth P. Lerner

  • Ian Murchie Thompson

Medical Centers

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Mayo Clinic, Phoenix, AZ

  • Johns Hopkins University Greenberg Bladder Cancer Institute, Baltimore, MD

  • University of Colorado Hospital, Aurora, CO

  • University of Utah-Huntsman Cancer Institute, Salt Lake City, UT

  • University of California, San Francisco, San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Johns Hopkins Hospital, Baltimore, MD

  • National Cancer Institute, Bethesda, MD

  • McGill University Health Centre, Montreal, QC, Canada

  • University of California, San Francisco, San Francisco, CA

  • SWOG, San Antonio, TX

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Baylor College of Medicine, Houston, TX

  • CHRISTUS Medical Center Hospital, San Antonio, TX

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved